Lexaria Bioscience (LEXX) Income from Non-Controlling Interests (2014 - 2026)
Lexaria Bioscience's (LEXX) quarterly Income from Non-Controlling Interests came in at -$2753.0 in Q1 2026, up 26.78% year-on-year from -$2171.4 in Q1 2025, and down 10.3% quarter-over-quarter from -$2496.0 in Q4 2025.
Lexaria Bioscience (LEXX) Income from Non-Controlling Interests (2014 - 2026) Analysis & Trends
Lexaria Bioscience has disclosed Income from Non-Controlling Interests across 12 years of filings, most recently posting -$2753.0 for Q1 2026.
- Income from Non-Controlling Interests for Q1 2026 came in at -$2753.0, up 26.78% year-over-year; the trailing twelve-month figure through Feb 2026 was -$8153.0 (up 26.48% YoY), and the FY2025 annual result was -$9593.0, up 27.92% from the prior year.
- Income from Non-Controlling Interests came in at -$2753.0 for Q1 2026 at Lexaria Bioscience, down from -$2496.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$1390.0 in Q3 2025 to a low of -$45696.0 in Q3 2022.
- The 5-year median for Income from Non-Controlling Interests is -$3760.0 (2025), against an average of -$10575.4.
- Across the five-year window, Income from Non-Controlling Interests sank 270.62% in 2022 and soared 81.63% in 2024, its largest moves.
- Lexaria Bioscience's Income from Non-Controlling Interests stood at -$13362.0 in 2022, then surged by 57.23% to -$5715.0 in 2023, then jumped by 48.75% to -$2929.0 in 2024, then grew by 14.78% to -$2496.0 in 2025, then decreased by 10.3% to -$2753.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$2753.0 (Q1 2026), -$2496.0 (Q4 2025), and -$1390.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 | -2,753.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -2,753.00 |
| Nov 30, 2025 | -2,496.00 |
| Aug 31, 2025 | -1,390.00 |
| May 31, 2025 | -1,514.00 |
| Feb 28, 2025 | -3,760.00 |
| Nov 30, 2024 | -2,929.00 |
| Aug 31, 2024 | -1,781.00 |
| May 31, 2024 | -2,619.00 |
| Feb 29, 2024 | -3,194.00 |
| Nov 30, 2023 | -5,715.00 |
| Aug 31, 2023 | -9,696.00 |
| May 31, 2023 | -12,061.00 |
| Feb 28, 2023 | -12,507.00 |
| Nov 30, 2022 | -13,362.00 |
| Aug 31, 2022 | -45,696.00 |
| May 31, 2022 | -35,413.00 |
| Feb 28, 2022 | -22,895.00 |
| Nov 30, 2021 | -10,325.00 |
| Aug 31, 2021 | -124,573.00 |
| May 31, 2021 | -9,555.00 |